Publications

Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). by Farrell DJ, Sader HS, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (6): 533-539

Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus (MRSA) strains with reduced susceptibility to daptomycin, linezolid, vancomycin and strains with defined SCCmec types. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 323-327

Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. by Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Florl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J and Turnidge J published in Antimicrob. Agents Chemother. 2014; 58 (4): 2006-2012

Detection of NDM-1-producing Enterobacteriaceae in Romania: Report of the SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Flonta M, Jones RN and Castanheira M published in J. Med. Microbiol. 2014; 63 (Pt 3): 483-484

Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. by Castanheira M, Jones RN and Sader HS published in J. Chemother. 2014; 26 (4): 202-210

Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-2011 in 14 European and Mediterranean countries. by Castanheira M, Deshpande LM, Costello A, Davies TA and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (7): 1804-1814

Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: Results from United States and European hospitals (2009-2011). by Sader HS, Flamm RK and Jones RN published in J. Chemother. 2014; 26 (3): 133-138

Antimicrobial susceptibility of Gram-negative organisms isolated from patients hospitalized with pneumonia in United States and European hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (4): 328-334

Activity of oritavancin tested against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide. by Mendes RE, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1579-1581

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004 – 2012). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in J. Antimicrob. Chemother. 2014; 69 (6): 1582-1588

Post ß-lactamase inhibitor effect of tazobactam in combination with ceftolozane and tested against ESBL-producing strains. by Sader HS, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2434-2437

Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011). by Sader HS, Jones RN, Stilwell MG and Flamm RK published in Int. J. Antimicrob. Agents. 2014; 43 (3): 284-286

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2274-2280

Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida using CLSI methods and interpretive criteria. by Pfaller MA, Messer SA, Diekema DJ, Jones RN and Castanheira M published in J. Clin. Microbiol. 2014; 52 (1): 108-114

Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011). by Pfaller MA, Flamm RK, Sader HS and Jones RN published in Diag. Microbiol. Infect. Dis 2014; 78 (4): 422-428

Effects of breakpoint changes on carbapenem susceptibility rates of Enterobacteriaceae: Results from the SENTRY Antimicrobial Surveillance Program, United States, 2008 to 2012. by Rennie RP and Jones RN published in Can. J. Infect. Dis. Med. Microbiol. 2014; 25 (5): 285-287

Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011. by Pfaller MA, Jones RN and Castanheira M published in Mycoses 2014; 57 (10): 602-611

Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (3): 233-238

Avibactam reverts the ceftazidime MIC₉₀ of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value. by Flamm RK, Stone GG, Sader HS, Jones RN and Nichols WW published in J. Chemother. 2014; 26 (6): 333-338

Mutation-driven ß-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa isolates from USA hospitals. by Castanheira M, Mills JC, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (11): 6844-6850

Update on Acinetobacter species: Mechanisms of antimicrobial resistances and contemporary in vitro activity of minocycline and other treatment options. by Castanheira M, Mendes RE and Jones RN published in Clin. Infect. Dis. 2014; 59 (Suppl 6): S367-373

Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean: Two novel beta-lactamases (GES-22 and VIM-35) were detected. by Castanheira M, Costello SE, Woosley LN, Deshpande LM, Davies TA and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (12): 7358-7366

Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. by VanScoy BD, Mendes RE, Castanheira M, McCauley J, Bhavnani SM, Jones RN, Friedrich LV, Steenbergen JN and Ambrose PG published in Antimicrob. Agents Chemother. 2014; 58 (10): 6024-6031

Multicenter study of anidulafungin and micafungin MIC distributions and epidemiological cutoff values for eight Candida species and the CLSI M27-A3 broth microdilution method. by Pfaller MA, Espinel-Ingroff A, Bustamante B, Canton E, Diekema DJ, Fothergill A, Fuller J, Gonzalez GM, Guarro J, Lass-Florl C, Lockhart SR and Martin-Mazuelos published in Antimicrob. Agents Chemother. 2014; 58 (2): 916-922

Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States 2014. by Mendes RE, Flamm RK, Hogan PA, Ross JE and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (2): 1243-1247

Resistance surveillance program report for selected European nations (2011). by Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 429-436

Retrospective molecular analysis of DIM-1 metallo-ß-lactamase discovered in Pseudomonas stutzeri from India in 2000. by Deshpande LM, Jones RN, Woosley LN and Castanheira M published in Antimicrob. Agents Chemother. 2014; 58 (1): 596-598

Frequency of fks mutations among Candida glabrata isolates from a 10-year global collection of bloodstream infection isolates. by Castanheira M, Woosley LN, Messer SA, Diekema DJ, Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2014; 58 (1): 577-580

Contemporary diversity of ß-lactamases among Enterobacteriaceae in the nine United States census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent ß-lactamase groups. by Castanheira M, Farrell SE, Krause KM, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2014; 58 (2): 833-838

Activity of Echinocandins and Triazoles Against a Contemporary (2012) Worldwide Collection of Yeast and Moulds Collected from Invasive Infections, Lead author: Castanheira M/Pfaller M, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Ceftaroline Activity Tested against Bacterial Isolates from Pediatric Patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation (AWARE) Program for the United States (2011-2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Emerging Resistant Serotype 19A Streptococcus pneumoniae in Adults in the US, Lead author: Isturiz RE, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Role of an Older Tetracycline for Treatment of Multidrug-resistant Acinetobacter spp. Infections: Understanding the Enhanced Potency of Minocycline!, Lead author: Jones RN, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftolozane/Tazobactam and Comparator Agents Tested Against Pseudomonas aeruginosa Isolates from United States Medical Centers (2011-2012), Lead author: Farrell DJ, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Activity of Ceftazidime-Avibactam Tested Against Enterobacteriaceae Isolates with Characterized &#223-Lactamase Encoding Genes Collected from United States Hospitals During 2012, Lead author: Castanheira M, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Ceftolozane/tazobactam Activity Tested against Aerobic Gram-negative Organisms Isolated from Intraabdominal Infections in European and United States Hospitals (2012), Lead author: Farrell DJ, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Frequency of Occurrence and Antimicrobial Susceptibility of Gram-negative Organisms Isolated from Healthcare Associated Urinary Tract Infections: Results from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS), Lead author: Farrell DJ, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Ceftazidime-avibactam Activity Tested Against Contemporary (2012) Gram-negative Organisms Causing Bloodstream Infections in United States (USA) Medical Centers, Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Activity of Ceftazidime-Avibactam Tested Against Contemporary (2012) Pathogens from Urinary Tract and Intraabdominal Infections from Patients in the USA, Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2012: Regional Activity of Linezolid and Comparator Compounds, Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Evaluation of Daptomycin Activity Tested against 164,457 Bacterial Strains from Hospitalized Patients: Summary of 8 Years of Surveillance Program Worldwide (2005-2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline and Comparator Agents Tested Against Bacterial Isolates from Patients with Bacteremia in United States Medical Centers (2012), Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Contemporary (2012) Bacteria Isolated from Community-Acquired Respiratory Tract Infections, Including Oxacillin-resistant S. aureus, Lead author: Sader HS, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Antimicrobial Activity of Ceftaroline Tested against Multidrug Resistant (MDR) Streptococcus pneumoniae in the USA (2009-2012), Lead author: Flamm R, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Serotype distribution of Streptococcus pneumoniae recovered principally from non-sterile sites in patients aged =18 years in the US (2009-2011), Lead author: Hollingsworth RC, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Streptococcus pneumoniae serotype 3 recovered predominantly from non-sterile sites in patients aged =18 years in the USA (2009-2011), Lead author: Hewlett D, presented at ID Week, October 2 – 6, 2013, San Francisco, CA

Activity of the First-in-class Lpxc Inhibitor ACHN-975 and Comparators Tested against Gram-negative Organisms Including Isolates with Characterized Resistance Mechanisms, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Detection of fks Gene Hot Spot Mutations in Candida glabrata by CLSI Broth Microdilution Testing of Anidulafungin, Caspofungin and Micafungin using Epidemiological Cutoff Values, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Use of Micafungin as a Surrogate Marker to Predict Susceptibility and Resistance to Caspofungin among 3,747 Clinical Isolates of Candida using CLSI Methods and Interpretive Criteria, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO

Activity of Isavuconazole and Comparator Antifungals Tested against Contemporary (2012) Fungal Clinical Isolates Collected Worldwide, Lead author: Castanheira M, presented at 53rd annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 10 -13, 2013, Denver, CO